Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Research Grant, 2016
    Identification of Epigenetic Signatures in Blood as Biomarkers for Parkinson's Disease

    Study Rationale:
    Epigenetic processes (changes in gene expression), such as DNA methylation (mechanism that cells use to control gene expression), ensure proper functioning of genetic materials in...

  • Biomarker Development, 2015
    Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies

    Study Rationale:
    Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson’s disease (PD) pathology. Such an agent will help (i) diagnose PD earlier,...

  • Access to Data and Biospecimens, 2015
    Lysosomal Enzyme Activity and GBA1 Genotyping in Parkinson’s Disease

    Study Rationale:                   
    The dysfunction of the systems responsible for the clearance of the protein alpha-synuclein plays a major role in Parkinson’s disease (PD). The lysosome is an...

  • Therapeutic Pipeline Program, 2015
    Utilization of Aptamers to Prevent Protein Aggregation in Parkinson’s Disease

    Objective/Rationale:             
    The abnormal aggregation of a protein known as alpha-synuclein appears to play a critical role in Parkinson's disease. This project will explore a new type of...

  • Improved Biomarkers and Clinical Outcome Measures, 2015
    Developing Progression Markers of Parkinson’s Disease with Multimodal Structural MRI of Substantia Nigra and Locus Coeruleus

    Study Rationale:
    Substantia nigra pars compacta (SNpc) and locus coeruleus (LC) are key brain areas involved in Parkinson’s disease. The loss of important chemicals (dopamine and norepinephrine) made...

  • Research Grant Supplement, 2015
    Identification of the Parkin-binding Domain for SLP-2 as a Potential Therapeutic Target Supplement

    Promising Outcomes of Original Grant:
    The objective of our Rapid Response Innovation Awards-supported project was to identify the parkin domain that interacts with Stomatin-like protein 2 (SLP-2), a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.